Effect of High Cheese Consumption on Metabolic Syndrome Risk Factors
NCT ID: NCT02616471
Last Updated: 2018-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
168 participants
INTERVENTIONAL
2014-02-28
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It will be explored whether high-fat and/or low-fat cheese consumption can be regarded healthy to consume for at-risk populations (assessed by within-group comparisons from baseline values) and if low-fat or non-fat alternatives to high-fat cheese should continue to be recommended (assessed by between-group comparisons).
In addition, it will be assessed if cheese consumption affects women and men differently as suggested by observational data. The present research project will examine the health effects of cheese as a food product per se and not as a sum of single nutrients, knowing that the single components of cheese cannot be adequately placebo-matched. A relatively high daily intake of high-fat cheese will be compared to a similar intake of low-fat cheese and with a carbohydrate control.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cheese and Human Health
NCT01140165
Dairy and Vegan Cheese: Effect on Satiety and Blood Glucose
NCT06568497
Effect of Cheese on Cardiovascular Risk
NCT01739153
Effect of Milk and Cheese on Fecal Fat Excretion and Blood Lipid
NCT01317251
Study of the Impact of Dairy Fat on Cardiovascular Health.
NCT02106208
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-fat cheese (HFC) group
The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US).
No further dairy and cheese consumption is allowed
High-fat cheese
Low-fat cheese (LFC) group
The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed.
Low-fat cheese
No-cheese/carbohydrate group (CTR)
For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed.
No-cheese/carbohydrate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-fat cheese
Low-fat cheese
No-cheese/carbohydrate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age 18-70
Waist circumference \> 80 cm for women / \> 94 cm for men
Plus at least one additional established risk factor for the metabolic syndrome using the following criteria:
* Elevated BP (Systolic BP \> 130 mmHg and/or diastolic BP \> 85 mmHg);
* Elevated triglycerides (\>1.7 mmol/l);
* Reduced HDL-C (\<1.0 mmol/l for men and \< 1.3 mmol/l for women);
* Elevated fasting glucose (\> 5.6 mmol/l). BMI 18.5 - 35 kg/m2
Exclusion Criteria
Milk allergy
Use of dietary supplements incl. multivitamins (2 months before and during the entire study period)
\>10 hours of strenuous physical activity per week
Use of prescription medicine which could affect the results of the present study including systemic glucocorticoids or medicine which have interactions with the intervention products (safety)
Drug or alcohol abuse
Blood donation \<1 month before study commencement and during study period
Simultaneous participation in other clinical studies
Pregnant or lactating women, or women who are planning to become pregnant within the next 6 months.
Inability to comply with the procedures required by the protocol
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Danish Dairy Research Foundation, Denmark
OTHER
Dairy Research Institute
OTHER
Dairy Farmers of Canada
OTHER
Centre National Interprofessionel de l'Economie Laitière
OTHER
Dairy Australia
INDUSTRY
Nederlandse Zuivel Organisatie
OTHER
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arne Astrup
Prof., MD, Head of Department, Department of Nutrition, Exercise and Sports
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arne Astrup, Prof, MD
Role: PRINCIPAL_INVESTIGATOR
Head of Department of Nutrition, Exercise and Sports
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nutrition, Exercise and Sport
Copenhagen, Frederiksberg, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raziani F, Tholstrup T, Kristensen MD, Svanegaard ML, Ritz C, Astrup A, Raben A. High intake of regular-fat cheese compared with reduced-fat cheese does not affect LDL cholesterol or risk markers of the metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2016 Oct;104(4):973-981. doi: 10.3945/ajcn.116.134932. Epub 2016 Aug 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B306
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.